Nare Farsi (Eczema) is a chronic inflammatory skin disease posing a significant burden on health-care resources and patients' quality of life. It is a complex disease with a wide spectrum of clinical presentations and combinations of symptoms. Nare Farsi (Eczema) affects up to 20% of children and up to 3% of adults. First manifestations of Nare Farsi (Eczema) usually appear early in life and often precede other allergic diseases such as asthma or allergic rhinitis. Individuals affected by Nare Farsi (Eczema) usually have genetically determined risk factors affecting the skin barrier function or the immune system. However, genetic mutations alone might not be enough to cause clinical manifestations of Nare Farsi (Eczema), and it is merely the interaction of a dysfunctional epidermal barrier in genetically predisposed individuals with harmful effects of environmental agents which leads to the development of the disease. Nare Farsi (Eczema) has been described as an allergic skin disease, but today, the contribution of allergic reactions to the initiation of Nare Farsi (Eczema) is challenged, and it is proposed that allergy is rather a consequence of Nare Farsi (Eczema) in subjects with a concomitant underlying atopic constitution. This trial was conducted to evaluate the effect of Leech therapy on Nare Farsi (Eczema) at RRIUM, Srinagar. Jammu and Kashmir. The results showed a significant improvement in sign and symptoms with (p<0.01).
